Nicoletta Cinone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9808314/publications.pdf

Version: 2024-02-01

10 papers	204 citations	1307366 7 h-index	10 g-index
10	10	10	225
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	BoNT-A for Post-Stroke Spasticity: Guidance on Unmet Clinical Needs from a Delphi Panel Approach. Toxins, 2021, 13, 236.	1.5	10
2	Ischemic Stroke in a 29-Year-Old Patient with COVID-19: A Case Report. Case Reports in Neurology, 2021, 13, 334-340.	0.3	3
3	Discontinuation of botulinum neurotoxin type-A treatment during COVID-19 pandemic: an Italian survey in post stroke and traumatic brain injury patients living with spasticity. European Journal of Physical and Rehabilitation Medicine, 2021, 57, 424-433.	1.1	13
4	Combined Effects of Isokinetic Training and Botulinum Toxin Type A on Spastic Equinus Foot in Patients with Chronic Stroke: A Pilot, Single-blind, Randomized Controlled Trial. Toxins, 2019, 11, 210.	1.5	22
5	Adjuvant treatments associated with botulinum toxin injection for managing spasticity: An overview of the literature. Annals of Physical and Rehabilitation Medicine, 2019, 62, 291-296.	1.1	50
6	Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke. Drugs, 2019, 79, 143-160.	4.9	38
7	Change in Coefficient of Fatigability Following Rapid, Repetitive Movement Training in Post-Stroke Spastic Paresis: A Prospective Open-Label Observational Study. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 2536-2540.	0.7	17
8	Ultrasonographic Evaluation of Botulinum Toxin Injection Site for the Medial Approach to Tibialis Posterior Muscle in Chronic Stroke Patients with Spastic Equinovarus Foot: An Observational Study. Toxins, 2017, 9, 375.	1.5	7
9	Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature. Toxins, 2015, 7, 3045-3056.	1.5	33
10	Postural and Balance Disorders in Patients with Parkinson's Disease: A Prospective Open-Label Feasibility Study with Two Months of Action Observation Treatment. Parkinson's Disease, 2015, 2015, 1-7.	0.6	11